Larotrectinib Compared With Other TRK Inhibitors for TRK Fusion+ Lung TumorsAugust 7th 2022
David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.
EP. 4B: Understanding Treatment Resistance in First-Generation TRK Inhibitors for the Treatment of NTRK Fusion-Positive CancersMay 13th 2022
In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.
EP. 4A: First -generation TRK Inhibitors and Treatment Resistance in NTRK Fusion-positive CancersApril 27th 2022
In the third video interview of the series, David S. Hong, MD, from the University of Texas MD Anderson Cancer Center discusses the safety and efficacy of first-generation TRK inhibitors and reflects on challenges affecting next-generation TRK inhibitors including research into mechanisms of treatment resistance.
Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical CancerApril 1st 2019
<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.</p>